Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Spending Means No Let Up In Off-Label Use Investigations, Attorney Predicts

This article was originally published in The Pink Sheet Daily

Executive Summary

The federal government will seek to curb off-label use further as it becomes responsible for 45% of total drug spending under the new Medicare law, Morgan Lewis' Mahinka says.

You may also be interested in...



Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT

QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.

Omnicare Boosts Specialty Pharma Services With $235 Mil. RxCrossroads Buy

Acquisition will enable company to leverage "end-to-end" product development through post-commercialization offerings, company says. Omnicare is now in discussions with NeighborCare after raising its takeover bid to $1.55 bil.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel